These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
145 related articles for article (PubMed ID: 27826212)
21. Acute withdrawal and botulinum toxin A in chronic migraine with medication overuse: a double-blind randomized controlled trial. Pijpers JA; Kies DA; Louter MA; van Zwet EW; Ferrari MD; Terwindt GM Brain; 2019 May; 142(5):1203-1214. PubMed ID: 30982843 [TBL] [Abstract][Full Text] [Related]
22. Occipital nerve block for the short-term preventive treatment of migraine: A randomized, double-blinded, placebo-controlled study. Dilli E; Halker R; Vargas B; Hentz J; Radam T; Rogers R; Dodick D Cephalalgia; 2015 Oct; 35(11):959-68. PubMed ID: 25505035 [TBL] [Abstract][Full Text] [Related]
23. Efficacy of sumatriptan tablets in migraineurs self-described or physician-diagnosed as having sinus headache: a randomized, double-blind, placebo-controlled study. Ishkanian G; Blumenthal H; Webster CJ; Richardson MS; Ames M Clin Ther; 2007 Jan; 29(1):99-109. PubMed ID: 17379050 [TBL] [Abstract][Full Text] [Related]
24. Effects of ibudilast on oxycodone-induced analgesia and subjective effects in opioid-dependent volunteers. Cooper ZD; Johnson KW; Vosburg SK; Sullivan MA; Manubay J; Martinez D; Jones JD; Saccone PA; Comer SD Drug Alcohol Depend; 2017 Sep; 178():340-347. PubMed ID: 28688296 [TBL] [Abstract][Full Text] [Related]
25. Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of high-frequency episodic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b study. Bigal ME; Dodick DW; Rapoport AM; Silberstein SD; Ma Y; Yang R; Loupe PS; Burstein R; Newman LC; Lipton RB Lancet Neurol; 2015 Nov; 14(11):1081-90. PubMed ID: 26432182 [TBL] [Abstract][Full Text] [Related]
26. Botulinum toxin type A (BOTOX) for the prophylactic treatment of chronic daily headache: a randomized, double-blind, placebo-controlled trial. Mathew NT; Frishberg BM; Gawel M; Dimitrova R; Gibson J; Turkel C; Headache; 2005 Apr; 45(4):293-307. PubMed ID: 15836565 [TBL] [Abstract][Full Text] [Related]
28. Acetyl-l-carnitine versus placebo for migraine prophylaxis: A randomized, triple-blind, crossover study. Hagen K; Brenner E; Linde M; Gravdahl GB; Tronvik EA; Engstrøm M; Sonnewald U; Helde G; Stovner LJ; Sand T Cephalalgia; 2015 Oct; 35(11):987-95. PubMed ID: 25601916 [TBL] [Abstract][Full Text] [Related]
29. Speed of onset and efficacy of zolmitriptan nasal spray in the acute treatment of migraine: a randomised, double-blind, placebo-controlled, dose-ranging study versus zolmitriptan tablet. Charlesworth BR; Dowson AJ; Purdy A; Becker WJ; Boes-Hansen S; Färkkilä M CNS Drugs; 2003; 17(9):653-67. PubMed ID: 12828501 [TBL] [Abstract][Full Text] [Related]
30. DFN-02 (Sumatriptan 10 mg With a Permeation Enhancer) Nasal Spray vs Placebo in the Acute Treatment of Migraine: A Double-Blind, Placebo-Controlled Study. Lipton RB; Munjal S; Brand-Schieber E; Rapoport AM Headache; 2018 May; 58(5):676-687. PubMed ID: 29878341 [TBL] [Abstract][Full Text] [Related]
31. Topiramate for migraine prevention in children: a randomized, double-blind, placebo-controlled trial. Winner P; Pearlman EM; Linder SL; Jordan DM; Fisher AC; Hulihan J; Headache; 2005; 45(10):1304-12. PubMed ID: 16324162 [TBL] [Abstract][Full Text] [Related]
32. Topiramate versus amitriptyline in migraine prevention: a 26-week, multicenter, randomized, double-blind, double-dummy, parallel-group noninferiority trial in adult migraineurs. Dodick DW; Freitag F; Banks J; Saper J; Xiang J; Rupnow M; Biondi D; Greenberg SJ; Hulihan J; Clin Ther; 2009 Mar; 31(3):542-59. PubMed ID: 19393844 [TBL] [Abstract][Full Text] [Related]
34. Botulinum toxin type A as migraine preventive treatment in patients previously failing oral prophylactic treatment due to compliance issues. Cady R; Schreiber C Headache; 2008 Jun; 48(6):900-13. PubMed ID: 18047501 [TBL] [Abstract][Full Text] [Related]
35. A double-blind placebo-controlled pilot study of sublingual feverfew and ginger (LipiGesic™ M) in the treatment of migraine. Cady RK; Goldstein J; Nett R; Mitchell R; Beach ME; Browning R Headache; 2011; 51(7):1078-86. PubMed ID: 21631494 [TBL] [Abstract][Full Text] [Related]
36. Design, rationale, and baseline characteristics of the randomized double-blind phase II clinical trial of ibudilast in progressive multiple sclerosis. Fox RJ; Coffey CS; Cudkowicz ME; Gleason T; Goodman A; Klawiter EC; Matsuda K; McGovern M; Conwit R; Naismith R; Ashokkumar A; Bermel R; Ecklund D; Koepp M; Long J; Natarajan S; Ramachandran S; Skaramagas T; Thornell B; Yankey J; Agius M; Bashir K; Cohen B; Coyle P; Delgado S; Dewitt D; Flores A; Giesser B; Goldman M; Jubelt B; Lava N; Lynch S; Miravalle A; Moses H; Ontaneda D; Perumal J; Racke M; Repovic P; Riley C; Severson C; Shinnar S; Suski V; Weinstock-Gutman B; Yadav V; Zabeti A Contemp Clin Trials; 2016 Sep; 50():166-77. PubMed ID: 27521810 [TBL] [Abstract][Full Text] [Related]